Lixte Biotechnology entered into a Securities Purchase Agreement with accredited investors for a registered direct offering. The company sold 2,366,503 common shares at $6.31 per share and issued pre-funded warrants for 258,859 shares at $6.30 with a $0.0001 exercise price, exercisable immediately. Gross proceeds were approximately $16.6 million before expenses, and the offering closed on June 4, 2026. The transaction was conducted under Lixte’s effective shelf registration on Form S-3.
Agreement details:
- Agreement type: Securities Purchase Agreement for registered direct offering of common stock and pre-funded warrants
- Counterparty: Certain accredited investors
- Signed / Effective: Jun 02 2026 / same
- Reason: Raise capital
Original SEC Filing: LIXTE BIOTECHNOLOGY HOLDINGS, INC. [ LIXT ] – 8-K – Jun. 04, 2026
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.